While almost 57,000 labs received Medicare payments for labs performed last year, just three labs received 15 percent of the total Medicare lab payments.
MRM will develop immuno-MALDI mass spec assays to key cancer signaling proteins and test them in 100 breast and colorectal cancer samples provided by Exactis.
The test will be based on MRM Proteomics' immunoMALDI approach, which uses antibody enrichment of target proteins followed by analysis via MALDI mass spec.
The firm reported a 69 percent increase in product sales, driven by a 102 percent jump in cartridge sales and jump in research revenues.
Excluding the impact of the one-time sale of patents last year, the company's revenues climbed 38 percent on strong product and service revenue growth.
The agreement will enable Biocartis to commercialize the EGFR S492R resistance mutation as part of its liquid and solid biopsy RUO assays.
Pfizer will join Exact's sales reps to increase adoption of the colorectal cancer test; Wall Street reacted by sending Exact's shares up sharply.
VolitionRx has reached a definitive agreement with an investor for the placement of 5 million shares of the firm's stock at $1.80 per share.
The researchers argued that fecal immunochemical test could be used as "rule-in" test for patients with ambiguous symptoms.
The studies will evaluate VolitionRx's Nu.Q colorectal cancer screening platform in symptomatic and asymptomatic subjects throughout Asia.